82 related articles for article (PubMed ID: 10606166)
61. Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Schjødt K; Heilmann C; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 2003 Dec; 32(12):1125-33. PubMed ID: 14647266
[TBL] [Abstract][Full Text] [Related]
62. A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use.
Astori G; Malangone W; Adami V; Risso A; Dorotea L; Falasca E; Marini L; Spizzo R; Bigi L; Sala P; Tonutti E; Biffoni F; Rinaldi C; Del Frate G; Pittino M; Degrassi A
Blood Cells Mol Dis; 2001; 27(4):715-24; discussion 725-7. PubMed ID: 11778655
[TBL] [Abstract][Full Text] [Related]
63. Clinical utility in maximizing CD34+ cell count in stem cell grafts.
Burt RK
Oncologist; 1999; 4(3):265-8. PubMed ID: 10394595
[No Abstract] [Full Text] [Related]
64. Absence of a CD34- hematopoietic precursor population in recipients of CD34+ stem cell transplantation.
Kato S; Ando K; Nakamura Y; Muguruma Y; Sato T; Yabe H; Yabe M; Hattori K; Yasuda Y; Hotta T
Bone Marrow Transplant; 2001 Sep; 28(6):587-95. PubMed ID: 11607772
[TBL] [Abstract][Full Text] [Related]
65. Australasian CD34+ quality assurance program and rationale for the clinical utility of the single-platform method for CD34+ cell enumeration.
Chang A; Raik E; Marsden K; Ma DD
Cytotherapy; 2004; 6(1):50-61. PubMed ID: 14985167
[TBL] [Abstract][Full Text] [Related]
66. [The hematopoietic stem cell: biology and clinical applications].
Consolini R; Legitimo A; Calleri A
Pathologica; 2001 Feb; 93(1):2-14. PubMed ID: 11294014
[TBL] [Abstract][Full Text] [Related]
67. High stem cell dose in haemopoietic transplantation: is it always beneficial?
Urbano-Ispizua A
Leukemia; 2003 Aug; 17(8):1467-9. PubMed ID: 12886233
[No Abstract] [Full Text] [Related]
68. CD34: structure, biology, and clinical utility.
Krause DS; Fackler MJ; Civin CI; May WS
Blood; 1996 Jan; 87(1):1-13. PubMed ID: 8547630
[No Abstract] [Full Text] [Related]
69. Clinical utility in maximizing CD34+ cell count in stem cell grafts.
Burt RK
Stem Cells; 1999; 17(6):373-6. PubMed ID: 10606166
[TBL] [Abstract][Full Text] [Related]
70. Ex vivo manipulation of hematopoietic stem and progenitor cells.
Kanz L; Brugger W; Scheding S
Stem Cells; 1998; 16 Suppl 1():199-204. PubMed ID: 11012163
[TBL] [Abstract][Full Text] [Related]
71. Flow cytometric enumeration and immunophenotyping of hematopoietic stem and progenitor cells.
Gratama JW; Sutherland DR; Keeney M; Papa S
J Biol Regul Homeost Agents; 2001; 15(1):14-22. PubMed ID: 11388740
[TBL] [Abstract][Full Text] [Related]
72.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
